Granahan Investment Management Inc. MA boosted its holdings in argenx SE – (NASDAQ:ARGX) by 102.6% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 95,419 shares of the company’s stock after acquiring an additional 48,319 shares during the quarter. Granahan Investment Management Inc. MA’s holdings in argenx were worth $7,906,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Atria Investments LLC acquired a new stake in argenx in the second quarter valued at about $213,000. Fred Alger Management Inc. boosted its stake in argenx by 50.0% in the second quarter. Fred Alger Management Inc. now owns 3,000 shares of the company’s stock valued at $249,000 after buying an additional 1,000 shares in the last quarter. Aperio Group LLC acquired a new stake in argenx in the first quarter valued at about $268,000. Dimensional Fund Advisors LP acquired a new stake in argenx in the first quarter valued at about $498,000. Finally, US Bancorp DE acquired a new stake in argenx in the first quarter valued at about $598,000. 56.14% of the stock is currently owned by institutional investors and hedge funds.
ARGX has been the topic of several research analyst reports. Cowen reaffirmed a “buy” rating on shares of argenx in a research note on Thursday, June 14th. Stifel Nicolaus initiated coverage on argenx in a research note on Thursday. They set a “buy” rating and a $139.00 price target on the stock. Nomura initiated coverage on argenx in a research note on Friday, June 29th. They set a “buy” rating and a $161.00 price target on the stock. JMP Securities lifted their price target on argenx from $93.00 to $130.00 and gave the company a “positive” rating in a research note on Monday, June 18th. Finally, ValuEngine raised argenx from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. argenx presently has an average rating of “Buy” and a consensus target price of $125.14.
Shares of ARGX opened at $93.78 on Monday. argenx SE – has a 1 year low of $21.25 and a 1 year high of $103.00. The stock has a market cap of $2.87 billion, a PE ratio of -66.99 and a beta of 2.07.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: Closed-End Mutual Funds (CEFs)
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.